- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07548541
Acute Effects of Creatine and L-Arginine Co-Supplementation on Anaerobic and Cognitive Performance in Recreationally Active Males
Acute Effects of Creatine and L-Arginine Co-Supplementation on Anaerobic Power, Jump Performance, and Cognitive Reaction Time in Recreationally Active Males: A Randomized Crossover Trial
Study Overview
Status
Intervention / Treatment
Detailed Description
Creatine monohydrate and L-arginine are widely used ergogenic supplements that may influence performance through different physiological mechanisms. Creatine contributes to rapid adenosine triphosphate resynthesis through phosphocreatine availability, whereas L-arginine serves as a precursor for nitric oxide synthesis and may enhance blood flow and substrate delivery during exercise. Their combined administration may therefore produce complementary effects on physical and cognitive performance.
This study uses a randomized, double-blind, four-treatment crossover design in recreationally active adult males. Each participant completes four conditions: placebo, creatine monohydrate, L-arginine, and combined creatine plus L-arginine. Sessions are separated by at least 72 hours, and all testing is conducted at the same time of day. Supplementation is administered 60 minutes before performance testing. Creatine is provided as a single acute dose of 0.3 g/kg, L-arginine as 6 g, and the placebo as a matched control beverage.
Outcome assessments include the Running-Based Anaerobic Sprint Test for repeated-sprint power, the countermovement jump test for explosive lower-body performance, and the Stroop Color-Word Test for cognitive reaction time and accuracy. The primary objective is to examine whether acute co-supplementation with creatine and L-arginine improves anaerobic and cognitive outcomes more than placebo or either supplement alone.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Malatya
-
Malatya, Malatya, Turkey (Türkiye), 44280
- Inonu University, Faculty of Sport Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male recreational athletes aged 18 years or older
- At least 2 years of regular participation in organized sport
- Apparently healthy and able to complete high-intensity exercise testing
Exclusion Criteria:
- Known orthopedic, neurological, cardiovascular, pulmonary, or metabolic disorders
- Use of anabolic steroids or performance-enhancing drugs within the previous 3 months
- Use of psychoactive or stimulant substances during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Participants received 6 g sucrose dissolved in 250 mL of water as the placebo condition.
|
Placebo beverage containing 6 g sucrose dissolved in 250 mL of water.
|
|
Experimental: Creatine
Participants received a single acute dose of creatine monohydrate at 0.3 g/kg dissolved in 250 mL of water.
|
Acute oral creatine monohydrate supplementation at 0.3 g/kg body mass.
|
|
Experimental: L-Arginine
Participants received a single acute dose of 6 g L-arginine dissolved in 250 mL of water.
|
Acute oral L-arginine supplementation at a dose of 6 g.
|
|
Experimental: Creatine + L-Arginine
Participants received combined acute supplementation with creatine monohydrate at 0.3 g/kg plus 6 g L-arginine in 250 mL of water.
|
Acute oral creatine monohydrate supplementation at 0.3 g/kg body mass.
Acute oral L-arginine supplementation at a dose of 6 g.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RAST Average Power
Time Frame: 60 minutes after supplementation, during the testing session
|
Average power during the Running-Based Anaerobic Sprint Test following acute supplementation.
|
60 minutes after supplementation, during the testing session
|
|
RAST Peak Power
Time Frame: 60 minutes after supplementation, during the testing session
|
Peak power during the Running-Based Anaerobic Sprint Test following acute supplementation.
|
60 minutes after supplementation, during the testing session
|
|
Countermovement Jump Height
Time Frame: 60 minutes after supplementation, during the testing session
|
Best countermovement jump height measured using the Optojump system following acute supplementation.
|
60 minutes after supplementation, during the testing session
|
|
Stroop Incongruent Median Reaction Time
Time Frame: 60 minutes after supplementation, during the testing session
|
Median reaction time in the incongruent condition of the computerized Stroop Color-Word Test following acute supplementation.
|
60 minutes after supplementation, during the testing session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
RAST Minimum Power
Time Frame: 60 minutes after supplementation, during the testing session
|
Minimum power during the Running-Based Anaerobic Sprint Test following acute supplementation.
|
60 minutes after supplementation, during the testing session
|
|
RAST Fatigue Index
Time Frame: 60 minutes after supplementation, during the testing session
|
Fatigue index during the Running-Based Anaerobic Sprint Test following acute supplementation.
|
60 minutes after supplementation, during the testing session
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- d'Unienville NMA, Blake HT, Coates AM, Hill AM, Nelson MJ, Buckley JD. Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance: a systematic review and meta-analysis of randomised controlled trials. J Int Soc Sports Nutr. 2021;18:76. https://doi.org/10.1186/s12970-021-00472-y
- Nyawose S, Naidoo R, Naumovski N, McKune AJ. The Effects of Consuming Amino Acids L-Arginine, L-Citrulline (and Their Combination) as a Beverage or Powder, on Athletic and Physical Performance: A Systematic Review. Beverages. 2022;8:48. https://doi.org/10.3390/beverages8030048
- Meixner B, Stegmaier J, Renner P, Koehler K, Yang W-H, Sperlich B. Supplementation of Creatine Monohydrate Improves Sprint Performance but Has no Effect on Glycolytic Contribution: A Nonrandomized, Placebo-Controlled Crossover Trial in Trained Cyclists. Curr Dev Nutr. 2025;9:104561. https://doi.org/10.1016/j.cdnut.2025.104561
- Vargas-Molina S, García-Sillero M, Kreider RB, Salinas E, Petro JL, Benítez-Porres J, et al. A randomized open-labeled study to examine the effects of creatine monohydrate and combined training on jump and scoring performance in young basketball players. J Int Soc Sports Nutr. 2022;19:529-42. https://doi.org/10.1080/15502783.2022.2108683
- Fernández-Landa J, Santibañez-Gutierrez A, Todorovic N, Stajer V, Ostojic SM. Effects of Creatine Monohydrate on Endurance Performance in a Trained Population: A Systematic Review and Meta-analysis. Sports Medicine. 2023;53:1017-27. https://doi.org/10.1007/s40279-023-01823-2
- Kerksick CM, Wilborn CD, Roberts MD, Smith-Ryan A, Kleiner SM, Jäger R, et al. ISSN exercise & sports nutrition review update: research & recommendations. J Int Soc Sports Nutr. 2018;15. https://doi.org/10.1186/s12970-018-0242-y
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INU-CRLA-2025-01
- Approval No: 2025/6879 (Other Identifier: Inonu University)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Danone NutriciaCompletedHealthy Elderly | Healthy VolunteersChina
-
National and Kapodistrian University of AthensCompletedHealthy Adults | Healthy Volunteers OnlyGreece
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Chong Kun Dang PharmaceuticalUnknownHypertension | DyslipidemiasKorea, Republic of